

# LY341495

**Catalog No: tcsc0343**



## Available Sizes

---

**Size:** 2mg

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg



## Specifications

---

**CAS No:**

201943-63-7

**Formula:**

$C_{20}H_{19}NO_5$

**Pathway:**

GPCR/G Protein

**Target:**

mGluR

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

353.37


## Product Description

LY341495 is a **metabotropic glutamate receptor (mGluR)** antagonist with **IC<sub>50</sub>**s of 2.9 nM, 10 nM, 170 nM for mGluR-2, mGluR-

3, mGluR-8, respectively.

IC50 & Target: IC50: 2.9 nM (mGluR-2, human), 10 nM (mGluR-3, human), 170 nM (mGluR-8, human)

**In Vivo:** LY341495 (0.3, 1, and 3 mg/kg, i.p.) displays a lower level of discrimination in rats<sup>[1]</sup>. LY341495 (3.0 mg/kg) decreases Dvl-2, pGSK-3 $\alpha$ / $\beta$  and  $\beta$ -catenin protein levels but Dvl-1, Dvl-3 and GSK-3 $\alpha$ / $\beta$  are unaffected in both the PFC and STR. LY341495 has the generally the opposite effect following acute and chronic administration compared to mGlu2/3 agonist, LY379268<sup>[2]</sup>. LY341495 (3 mg/kg, i.p., 2.5 h) -induced c-Fos expression is not altered in either KO brain. LY341495 is almost inactive in the central extended amygdala [central nucleus of the amygdala, lateral (CeL) and bed nucleus of the stria terminalis, laterodorsal (BSTLD)] in mGluR3-KO mice<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!